History

Aug 2012

Proximagen Group plc acquired by Upsher-Smith Laboratories, Inc.

Nov 2011

Proximagen and Altacor sign agreement for 5HT2c.

Sept 2011

Proximagen signs a strategic partnership agreement with H. Lundbeck A/S, involving a £10.3m investment in Proximagen by Lundbeck.

Dec 2010

Proximagen acquires two CNS drug development programmes from GlaxoSmithKline.

May 2010

Proximagen Neuroscience plc changes its name to Proximagen Group plc.

April 2010

Proximagen sub-licences the North American rights to tonabersat to Upsher-Smith Laboratories Inc.

February 2010

Proximagen acquires Minster Pharmaceuticals plc.

January 2010

Proximagen announces a cash offer for Minster Pharmaceuticals plc which has two clinical stage assets, tonabersat and sabcomeline. Worldwide rights to both compounds were acquired by Minster from GlaxoSmithKline and these compounds benefit from comprehensive safety tolerance data following investment by GSK.

November 2009

Proximagen makes its first corporate acquisition and buys Cambridge Biotechnology Limited from Biovitrum AB. The Company also acquires certain pre-clinical and clinical stage assets from Biovitrum A.B.

October 2009

Proximagen acquires the compound naluzotan, the safety and tolerability of which has been demonstrated in the clinic. The Company is now exploring the potential of this compound for treating both epilepsy and levodopa-induced dyskinesia.

June 2009

The Company raises £50 million in the first stage of its plan to become one of the world's leading companies developing therapeutics for patients suffering from diseases of the CNS. Funds are earmarked for the acquisition and development of clinical stage CNS programmes.

July 2008

Proximagen signs a $232 million licensing agreement with Upsher-Smith Laboratories, Inc. for its lead programme, PRX1, which includes a $6 million equity investment in Proximagen.

March 2005

Proximagen Neuroscience plc undertakes an Initial Public Offering raising £13.5m (gross) to fund the development of the Company's early stage drug discovery programmes which were centred on neurodegenerative disease. The Company's shares are listed on the AIM market of the London Stock Exchange.

March 2004

Proximagen receives financial backing from IP Group plc, one of the UK's leading companies focusing on the commercialisation of intellectual property originating from research intensive institutions.

November 2003

Proximagen Limited is founded. The company was a spin-out from King's College London and was built around the work of Professor Peter Jenner, a key opinion leader in the field of Parkinson's disease.